• C8-HSL Drives Lung Cancer Cell Progression via PI3K/AKT/ERK

  2026-06-30

  The reference study reveals that C8-HSL, a bacterial quorum-sensing molecule, directly promotes proliferation, migration, and invasion of lung cancer cells through activation of the PI3K/AKT/ERK signaling cascade. These findings bridge microbial signaling with tumor progression, highlighting C8-HSL as a risk factor and potential target in lung cancer biology.

• FAISL lncRNA Blocks FAK Proteolysis, Driving TNBC Progressio

  2026-06-30

  The study reveals that the long noncoding RNA FAISL stabilizes FAK protein by preventing Calpain 2-mediated proteolysis, thereby promoting triple negative breast cancer (TNBC) progression and metastasis. This mechanistic insight identifies FAISL as a potential therapeutic target and highlights new complexity in the regulation of FAK signaling in aggressive breast cancers.

• Deferasirox Fe3+ Chelate: Evolving Myeloid Biology & Transla

  2026-06-29

  This thought-leadership article synthesizes mechanistic advances and translational strategies for Deferasirox Fe3+ chelate (Exjade), highlighting its unique role in iron overload research and myeloid cell biology. The narrative integrates recent findings on NF-κB modulation, mitochondrial ROS, and haematopoietic differentiation, offering protocol guidance and a forward-looking perspective for researchers in beta-thalassemia, MDS, and chronic anemia.

• Honokiol: Applied Workflows for NF-κB Pathway Inhibition in

  2026-06-29

  Honokiol, a potent NF-κB pathway inhibitor and antioxidant, enables precise modulation of inflammatory and tumorigenic pathways in advanced in vitro studies. This article details optimized experimental workflows, troubleshooting strategies, and protocol enhancements for leveraging Honokiol in quantitative cancer drug response assays.

• Sulfisomidine in Microbial Metabolism: Translational Insight

  2026-06-28

  Explore how Sulfisomidine (sulfamethin) uniquely advances enzyme kinetics and antibacterial research, drawing on clinical evidence and practical assay guidance. This article delivers deeper insight into microbial metabolism and translational protocol design.

• CLEC5A and ISG20: Causal Links to Atherosclerosis Progressio

  2026-06-27

  Zhang et al. (2025) demonstrate, through integrated Mendelian randomization and eQTL analysis, that CLEC5A and ISG20 are causally associated with atherosclerosis risk. Their experimental validation uncovers ISG20’s mechanistic role in promoting macrophage-driven lipid accumulation and inflammation, with implications for therapeutic targeting and experimental biomarker detection.

• Sulfisomidine (Sulfamethin): Protocols and Applied Research

  2026-06-26

  Sulfisomidine (sulfamethin) stands out as both a short-acting sulfonamide antibacterial and a robust enzyme kinetics inhibitor, making it indispensable for studies from microbial metabolism to hPON1-targeted oxidative stress research. This article delivers actionable workflows, troubleshooting guidance, and comparative insights, drawing from landmark studies and advanced protocols.

• CDK4 Controls 4E-BP1 and Cap-Dependent Translation in Mitosi

  2026-06-26

  Mitchell et al. uncover cyclin-dependent kinase 4 (CDK4) as a direct regulator of 4E-BP1 phosphorylation, promoting cap-dependent translation during the critical mitosis-to-G1 transition. This work expands the landscape of translational control in cell cycle progression and highlights new mechanistic intersections with kinase signaling pathways relevant to cancer and drug resistance.

• Distinct Apoptotic Pathways in BMECs Induced by Candida krus

  2026-06-25

  Miao et al. (2023) reveal that Candida krusei triggers apoptosis in bovine mammary epithelial cells (BMECs) via different mechanisms depending on its morphological phase. Their work distinguishes the mitochondrial and death receptor pathways in fungal mastitis, establishing a foundation for targeted research and intervention strategies.

• EZ Cap™ EPO mRNA: Redefining Translational Neurorepair

  2026-06-25

  This thought-leadership article explores the mechanistic and strategic advances enabled by EZ Cap™ EPO mRNA (ψUTP) for translational researchers. It synthesizes evidence from cutting-edge studies on targeted mRNA nanotherapeutics in spinal cord injury, highlighting how next-generation mRNA design, delivery, and stability engineering open new frontiers in neurorepair and erythropoiesis. The article details best practices, competitive insights, and future outlooks for deploying human erythropoietin mRNA platforms, with contextual product recommendations and critical evaluation of cross-domain potential.

• PDHA1 Succinylation Drives Immune Evasion in Cholangiocarcin

  2026-06-24

  This study uncovers how succinylation of PDHA1 at lysine 83 in cholangiocarcinoma rewires the tricarboxylic acid cycle, promoting alpha-ketoglutarate accumulation and suppressing macrophage antigen presentation. These findings reveal a novel metabolic-immune axis mediating tumor immune escape and suggest targeting PDHA1 succinylation as a strategy to enhance chemotherapy efficacy.

• Gut-Brain Cholinergic Signaling in Microbiota-Mediated Seizu

  2026-06-23

  Jia et al. identify a gut-brain cholinergic signaling pathway through which Bacteroides fragilis suppresses seizures in pediatric refractory epilepsy. Their study reveals mechanistic links between gut microbiota, vagal acetylcholine neurotransmitter transmission, and clinical seizure reduction, establishing a new translational axis for therapeutic intervention.

• LY2886721: Precision BACE1 Inhibition and Synaptic Safety in

  2026-06-23

  Explore how LY2886721, a potent BACE inhibitor, enables amyloid beta reduction with synaptic safety in Alzheimer's disease research. This article delivers a uniquely deep analysis of dosing, mechanistic action, and translational considerations, going beyond standard overviews.

• 2'3'-cGAMP: Redefining STING Pathway Strategies in Oncology

  2026-06-22

  This article delivers a thought-leadership perspective for translational researchers on leveraging 2'3'-cGAMP (sodium salt) as both a mechanistic probe and strategic lever in advancing the cGAS-STING pathway for next-generation cancer immunotherapy. Drawing from cutting-edge findings on senescence, SASP, and STING signaling in small cell lung cancer, we contextualize APExBIO’s high-affinity 2'3'-cGAMP (sodium salt) as an enabling benchmark for preclinical studies and experimental design. The discussion integrates recent literature, highlights competitive advantages, and provides actionable guidance on protocol parameters and translational implications.

• LY2886721: Nanomolar BACE1 Inhibitor for Alzheimer’s Researc

  2026-06-22

  LY2886721 is a potent, orally bioavailable BACE1 inhibitor that enables effective amyloid beta reduction in Alzheimer’s disease research models. Its nanomolar IC50 and validated synaptic safety at moderate doses make it a benchmark tool for dissecting amyloid precursor protein processing and therapeutic exploration.

15741 records 1/1050 page Next 12345 下5页 Last page